Cargando…
A rare case of prostate neuroendocrine tumor: A case report
Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574441/ https://www.ncbi.nlm.nih.gov/pubmed/36263212 http://dx.doi.org/10.3389/fonc.2022.1009146 |
_version_ | 1784811106894610432 |
---|---|
author | Teh, Shunxing Inn, Fam Xeng Rizuana, Iqbal Hussain WM, Wan Muhaizan |
author_facet | Teh, Shunxing Inn, Fam Xeng Rizuana, Iqbal Hussain WM, Wan Muhaizan |
author_sort | Teh, Shunxing |
collection | PubMed |
description | Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge and hard prostate mass. He underwent a transrectal ultrasound-guided (TRUS) biopsy of the prostate. Histopathology showed high-grade small cell neuroendocrine carcinoma. Immunohistochemical markers were positive for synaptophysin with a Ki67 index of almost 100%. However, CD56 and chromogranin A markers were negative. Magnetic resonance imaging (MRI) of the prostate showed a prostate mass with invasion to the rectum, while contrast-enhanced computed tomography of the thorax, abdomen, and pelvis (CT TAP) ruled out metastasis. A multidisciplinary team discussion was carried out, and a decision was made for concurrent chemotherapy and radiation (cisplatin and etoposide for 4 cycles and 70 Gy, 35 fractions). There is a lack of consensus on the management of SCPC. The main modality of management in advanced (stage IV) disease is chemotherapy. It is a highly aggressive tumor with a poor prognosis and is not responsive to hormonal therapy. |
format | Online Article Text |
id | pubmed-9574441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95744412022-10-18 A rare case of prostate neuroendocrine tumor: A case report Teh, Shunxing Inn, Fam Xeng Rizuana, Iqbal Hussain WM, Wan Muhaizan Front Oncol Oncology Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge and hard prostate mass. He underwent a transrectal ultrasound-guided (TRUS) biopsy of the prostate. Histopathology showed high-grade small cell neuroendocrine carcinoma. Immunohistochemical markers were positive for synaptophysin with a Ki67 index of almost 100%. However, CD56 and chromogranin A markers were negative. Magnetic resonance imaging (MRI) of the prostate showed a prostate mass with invasion to the rectum, while contrast-enhanced computed tomography of the thorax, abdomen, and pelvis (CT TAP) ruled out metastasis. A multidisciplinary team discussion was carried out, and a decision was made for concurrent chemotherapy and radiation (cisplatin and etoposide for 4 cycles and 70 Gy, 35 fractions). There is a lack of consensus on the management of SCPC. The main modality of management in advanced (stage IV) disease is chemotherapy. It is a highly aggressive tumor with a poor prognosis and is not responsive to hormonal therapy. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9574441/ /pubmed/36263212 http://dx.doi.org/10.3389/fonc.2022.1009146 Text en Copyright © 2022 Teh, Inn, Rizuana and WM https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Teh, Shunxing Inn, Fam Xeng Rizuana, Iqbal Hussain WM, Wan Muhaizan A rare case of prostate neuroendocrine tumor: A case report |
title | A rare case of prostate neuroendocrine tumor: A case report |
title_full | A rare case of prostate neuroendocrine tumor: A case report |
title_fullStr | A rare case of prostate neuroendocrine tumor: A case report |
title_full_unstemmed | A rare case of prostate neuroendocrine tumor: A case report |
title_short | A rare case of prostate neuroendocrine tumor: A case report |
title_sort | rare case of prostate neuroendocrine tumor: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574441/ https://www.ncbi.nlm.nih.gov/pubmed/36263212 http://dx.doi.org/10.3389/fonc.2022.1009146 |
work_keys_str_mv | AT tehshunxing ararecaseofprostateneuroendocrinetumoracasereport AT innfamxeng ararecaseofprostateneuroendocrinetumoracasereport AT rizuanaiqbalhussain ararecaseofprostateneuroendocrinetumoracasereport AT wmwanmuhaizan ararecaseofprostateneuroendocrinetumoracasereport AT tehshunxing rarecaseofprostateneuroendocrinetumoracasereport AT innfamxeng rarecaseofprostateneuroendocrinetumoracasereport AT rizuanaiqbalhussain rarecaseofprostateneuroendocrinetumoracasereport AT wmwanmuhaizan rarecaseofprostateneuroendocrinetumoracasereport |